Top Markets
#1 Status Status +19.34%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.51%
#3 GoPlus Security GoPlus Security +14.26%
#4 Ontology Gas Ontology Gas +12.27%
#5 DMT-NAT DMT-NAT +8.99%
#6 Nillion Nillion +7.04%
#7 Provenance Blockchain Provenance Blockchain +7.02%
#8 Janction Janction +6.49%
#9 Cap Cap +6.34%
#10 Bedrock Bedrock +5.75%
Coin of the day
Status Status
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Renalytix Plc Renalytix Plc

Renalytix Plc

RNLX
Kedudukan dalam Saham #33998
Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc... Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc until its name change in June 2021, focuses on creating artificial intelligence-driven in vitro diagnostic tools for kidney ailments. Its primary product, KidneyIntelX, is an advanced diagnostic system that utilizes an AI-powered algorithm. This algorithm integrates multiple data sources, including scientifically validated blood markers, genetic predispositions, and individual patient information from electronic health records, to produce a distinct risk score for kidney disease. The company's technology is applied in various areas: identifying and predicting the course of kidney disease, informing clinical treatment, selecting patients for pharmaceutical trials, and discovering new therapeutic targets. Renalytix has formed several strategic collaborations, such as licensing agreements with Mount Sinai Health System for AI-assisted kidney disease diagnosis, with Joslin Diabetes Center, Inc. for developing biomarker-based kidney disease prediction products, and with Kantaro Biosciences LLC for laboratory tests to detect SARS-CoV-2 antibodies. Furthermore, it has partnered with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to introduce an innovative clinical care model aimed at improving kidney health outcomes and preventing disease advancement and failure in vulnerable populations.
Harga Saham
$0.1502
Disegerakkan terakhir: 2024-11-04
Modal Pasaran
$6.43M
Perubahan (1 hari)
-5.45%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Renalytix Plc (RNLX)

Kategori

Healthcare
Pendapatan untuk Renalytix Plc (RNLX)
Pendapatan pada Sep 2024 TTM: $-28.67M
Menurut laporan kewangan terkini Renalytix Plc, pendapatan semasa syarikat ialah $-28.67M. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $-46.22M, penurunan berbanding pendapatan pada tahun 2022 yang berjumlah $-45.25M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Renalytix Plc dari 2018 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
2026 (TTM) $-28.67M -14.29%
2024 $-33.45M -27.63%
2023 $-46.22M 2.14%
2022 $-45.25M 26.44%
2021 $-35.79M 237.30%
2020 $-10.61M 62.78%
2019 $-6.52M 1,459.33%
2018 $-418.00K 0.00%
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
GE HealthCare Technologies Inc. GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc.
GEHC.US
$2.04B -7,225.67%
US
Pro Medicus Limited Pro Medicus Limited
Pro Medicus Limited
PME.AX
$222.34M -875.49%
AU
BrightSpring Health Services, Inc. Common Stock BrightSpring Health Services, Inc. Common Stock
BrightSpring Health Services, Inc. Common Stock
BTSG.US
$295.53M -1,130.77%
US
Tempus AI, Inc. Tempus AI, Inc.
Tempus AI, Inc.
TEM.US
$-259.89M 806.47%
US
Signify Health, Inc. Signify Health, Inc.
Signify Health, Inc.
SGFY.US
- -
US